Cargando…

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

BACKGROUND: Adenosine receptor stress agents for myocardial perfusion imaging (MPI) may cause A(2B) and/or A(3) receptor-mediated bronchoconstriction, of particular concern to physicians testing patients with asthma or chronic obstructive pulmonary disease (COPD). METHODS: A Phase 4, randomized, dou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prenner, Bruce M., Bukofzer, Stan, Behm, Sarah, Feaheny, Kathleen, McNutt, Bruce E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395344/ https://www.ncbi.nlm.nih.gov/pubmed/22484721 http://dx.doi.org/10.1007/s12350-012-9547-4

Ejemplares similares

A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease
por: Ananthasubramaniam, Karthik, et al.
Publicado: (2012)

Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study
por: Tejani, Furqan H., et al.
Publicado: (2014)

The EXERRT trial: “EXErcise to Regadenoson in Recovery Trial”: A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol
por: Thomas, Gregory S., et al.
Publicado: (2017)

Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study
por: Townsend, Robert, et al.
Publicado: (2015)

Safety and tolerability of regadenoson CMR
por: Nguyen, Kim-Lien, et al.
Publicado: (2014)

Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge
por: Golzar, Yasmeen, et al.
Publicado: (2014)

Regadenoson in the detection of coronary artery disease
por: Buhr, Christiane, et al.
Publicado: (2008)

Cardiovascular effects and tolerance of adenosine versus regadenoson during cardiac MRI perfusion testing
por: Minor, Matthew, et al.
Publicado: (2015)

The Effect of Antihelminthic Treatment on Subjects with Asthma from an Endemic Area of Schistosomiasis: A Randomized, Double-Blinded, and Placebo-Controlled Trial
por: Almeida, Maria Cecilia F., et al.
Publicado: (2012)

Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast
por: Columbo, Michele
Publicado: (2017)

Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy
por: Brinkert, M., et al.
Publicado: (2013)

Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
por: Kudiganti, Venkateshwarlu, et al.
Publicado: (2016)

Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study
por: Vicknasingam, Balasingam, et al.
Publicado: (2020)

Synbiotics and Treatment of Asthma: A Double-Blinded, Randomized, Placebo-Controlled Clinical Trial
por: Hassanzad, Maryam, et al.
Publicado: (2019)

Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study
por: Huang, Kai, et al.
Publicado: (2022)

A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma
por: Colombo, Rhonda E., et al.
Publicado: (2016)

Nebulized Budesonide vs. Placebo in Adults with Asthma Attack; a Double Blind Randomized Placebo-Controlled Clinical Trial
por: Sheikh-Motahar-Vahedi, Hojat, et al.
Publicado: (2018)

Stress perfusion cardiac MRI with regadenoson and gadofoveset trisodium
por: Allen, Bradley D, et al.
Publicado: (2015)

Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging
por: Radwan, Sohab S., et al.
Publicado: (2019)

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
por: O’Donnell, John, et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation
por: Zubairi, Ali Bin Sarwar, et al.
Publicado: (2013)

Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study
por: Sengupta, Krishanu, et al.
Publicado: (2012)

Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure
por: Sarkkinen, Essi S., et al.
Publicado: (2018)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
por: Li, Haiyan, et al.
Publicado: (2020)

2553. Safety, tolerability and pharmacokinetics of HS-10366 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase 1 trial
por: Liu, Xiaoyan, et al.
Publicado: (2023)

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
por: Bagger, Yu, et al.
Publicado: (2023)

Residual effects of eszopiclone and placebo in healthy elderly subjects: a randomized double-blind study
por: Takahashi, Jun, et al.
Publicado: (2017)

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
por: Leubitz, Andi, et al.
Publicado: (2021)

Serious complications associated with regadenoson administration for myocardial perfusion imaging
por: Kitt, Therese, et al.
Publicado: (2014)

Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson
por: Bitar, Abbas, et al.
Publicado: (2015)

Severe Shivering as an Adverse Effect of Regadenoson Myocardial Perfusion Imaging
por: Ahmad, Tanjeev, et al.
Publicado: (2021)

Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
por: Muñiz-Sáenz-Diez, Javier, et al.
Publicado: (2023)

Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial
por: Sadrifar, Sina, et al.
Publicado: (2023)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
por: Gill, Anne, et al.
Publicado: (2010)

Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double‐blind, placebo‐controlled, crossover study
por: Cheng, Jocelyn Y., et al.
Publicado: (2020)

Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial
por: Moon, Heui-Soo, et al.
Publicado: (2010)

Effects of High Doses of Cholecalciferol in Normal Subjects: A Randomized Double-Blinded, Placebo-Controlled Trial
por: Nygaard, Birgitte, et al.
Publicado: (2014)

A double blind randomized placebo control crossover trial on the effect of dietary nitrate supplementation on exercise tolerance in stable moderate chronic obstructive pulmonary disease
por: Leong, Paul, et al.
Publicado: (2015)

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
por: Becker, Anna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rkksqov6hn03qpepuq5o3hkekv